Literature DB >> 29882463

Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation.

Maxine X Patel1, Faisil N Sethi2, Thomas Re Barnes3, Roland Dix4, Luiz Dratcu5, Bernard Fox6, Marina Garriga7, Julie C Haste8, Kai G Kahl9, Anne Lingford-Hughes10, Hamish McAllister-Williams11,12, Aileen O'Brien13, Caroline Parker14, Brodie Paterson15, Carol Paton16, Sotiris Posporelis17, David M Taylor18, Eduard Vieta7, Birgit Völlm19, Charlotte Wilson-Jones20, Laura Woods21.   

Abstract

The British Association for Psychopharmacology and the National Association of Psychiatric Intensive Care and Low Secure Units developed this joint evidence-based consensus guideline for the clinical management of acute disturbance. It includes recommendations for clinical practice and an algorithm to guide treatment by healthcare professionals with various options outlined according to their route of administration and category of evidence. Fundamental overarching principles are included and highlight the importance of treating the underlying disorder. There is a focus on three key interventions: de-escalation, pharmacological interventions pre-rapid tranquillisation and rapid tranquillisation (intramuscular and intravenous). Most of the evidence reviewed relates to emergency psychiatric care or acute psychiatric adult inpatient care, although we also sought evidence relevant to other common clinical settings including the general acute hospital and forensic psychiatry. We conclude that the variety of options available for the management of acute disturbance goes beyond the standard choices of lorazepam, haloperidol and promethazine and includes oral-inhaled loxapine, buccal midazolam, as well as a number of oral antipsychotics in addition to parenteral options of intramuscular aripiprazole, intramuscular droperidol and intramuscular olanzapine. Intravenous options, for settings where resuscitation equipment and trained staff are available to manage medical emergencies, are also included.

Entities:  

Keywords:  Acute disturbance; aggression; antipsychotics; benzodiazepines; de-escalation; psychiatric illness; rapid tranquillisation; violence

Mesh:

Substances:

Year:  2018        PMID: 29882463     DOI: 10.1177/0269881118776738

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  9 in total

1.  Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.

Authors:  Sheldon H Preskorn; Scott Zeller; Leslie Citrome; Jeffrey Finman; Joseph F Goldberg; Maurizio Fava; Rishi Kakar; Michael De Vivo; Frank D Yocca; Robert Risinger
Journal:  JAMA       Date:  2022-02-22       Impact factor: 157.335

Review 2.  Quality of smoking cessation advice in guidelines of tobacco-related diseases: An updated systematic review.

Authors:  Winifred Ekezie; Rachael L Murray; Sanjay Agrawal; Ilze Bogdanovica; John Britton; Jo Leonardi-Bee
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

Review 3.  Inhaled Loxapine for the Management of Acute Agitation in Bipolar Disorder and Schizophrenia: Expert Review and Commentary in an Era of Change.

Authors:  Bruno Pacciardi; Alfredo Calcedo; Thomas Messer
Journal:  Drugs R D       Date:  2019-03

4.  Predicting Inpatient Aggression in Forensic Services Using Remote Monitoring Technology: Qualitative Study of Staff Perspectives.

Authors:  Ben Greer; Katie Newbery; Matteo Cella; Til Wykes
Journal:  J Med Internet Res       Date:  2019-09-19       Impact factor: 5.428

5.  Effectiveness of De-Escalation in Reducing Aggression and Coercion in Acute Psychiatric Units. A Cluster Randomized Study.

Authors:  Andreja Celofiga; Blanka Kores Plesnicar; Jure Koprivsek; Miha Moskon; Dominik Benkovic; Hojka Gregoric Kumperscak
Journal:  Front Psychiatry       Date:  2022-04-07       Impact factor: 4.157

6.  The Utilization of a Rapid Agitation Scale and Treatment Protocol for Patient and Staff Safety in an Inpatient Psychiatric Setting.

Authors:  Tessa Manning; Sarah Beth Bell; Drew Dawson; Krista Kezbers; Micheal Crockett; Ondria Gleason
Journal:  Psychiatr Q       Date:  2022-08-25

7.  Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed.

Authors:  Leslie Citrome; Robert Risinger; Lavanya Rajachandran; Heather Robison
Journal:  Adv Ther       Date:  2022-08-24       Impact factor: 4.070

8.  Physical health monitoring after rapid tranquillisation: clinical practice in UK mental health services.

Authors:  Carol Paton; Clive E Adams; Stephen Dye; Oriana Delgado; Chike Okocha; Thomas R E Barnes
Journal:  Ther Adv Psychopharmacol       Date:  2019-12-18

Review 9.  Which Emergent Medication Should I Give Next? Repeated Use of Emergent Medications to Treat Acute Agitation.

Authors:  Veronica B Searles Quick; Ellen D Herbst; Raj K Kalapatapu
Journal:  Front Psychiatry       Date:  2021-12-07       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.